OCUL Ocular Therapeutix, Inc.
Legal ·
EyePoint, Inc. sued Ocular in Massachusetts state court on March 20, 2026 over alleged false statements about DURAVYU. The court denied a restraining order on April 13 and has not ruled on a preliminary injunction.
We have not published a story on Ocular Therapeutix yet. When there is news, it will appear here.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on retinal disease and ophthalmic products. Its lead investigational product, AXPAXLI (OTX-TKI), is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel technology. AXPAXLI is in a Phase 3 registrational program for wet age-related macular degeneration, known as the SOL program, and in a Phase 3 registrational program for diabetic retinal disease, including non-proliferative diabetic retinopathy, known as the HELIOS program. The company's commercial product DEXTENZA, a drug-eluting intracanalicular insert, is approved by the FDA for ocular inflammation and pain following ophthalmic surgery and for ocular itching associated with allergic conjunctivitis. The ELUTYX technology is also used in OTX-TIC, a travoprost intracameral hydrogel that completed a Phase 2 trial for open-angle glaucoma or ocular hypertension. The company is evaluating next steps for OTX-TIC. The exudative retinal disease market that AXPAXLI targets accounted for approximately $9.4 billion in U.S. annual estimated revenues in 2025, according to a third-party report. AffaMed Therapeutics Limited holds a license and collaboration for DEXTENZA and OTX-TIC in certain Asian geographies.
| Product or program | What it is | Stage |
|---|---|---|
| AXPAXLI (OTX-TKI) | Axitinib intravitreal hydrogel for wet AMD and diabetic retinal disease | Phase 3 |
| DEXTENZA | Drug-eluting intracanalicular insert for ocular inflammation and pain | FDA approved |
| OTX-TIC | Travoprost intracameral hydrogel for open-angle glaucoma or ocular hypertension | Phase 2 completed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $197.1 million | $127.6 million |
| Net income (loss) | -$265.9 million | -$193.5 million |
| Cash from operations | -$204.9 million | -$134.7 million |
| Cash and equivalents | $737.1 million | $392.1 million |
Our latest story on this, dated Aug 3, 2026: "Ocular Therapeutix faces EyePoint defamation suit; injunction ruling still pending". The story links the filing or release it is based on. Read the story.
Ocular Therapeutix, Inc. trades under the ticker OCUL on NASDAQ.
Ocular Therapeutix, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0OT; LS:A1180P; LSX:A1180P.
The SEC Central Index Key (CIK) for Ocular Therapeutix, Inc. is 1393434. Its filings are on SEC EDGAR.
219,615,868 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-03.
Our directory records Ocular Therapeutix, Inc. under United States.
Our directory classifies Ocular Therapeutix, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Ocular Therapeutix, Inc. is US67576A1007.
aibio.space lists Ocular Therapeutix, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on retinal disease and ophthalmic products. Its lead investigational product, AXPAXLI (OTX-TKI), is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel technology.
AXPAXLI (OTX-TKI): Axitinib intravitreal hydrogel for wet AMD and diabetic retinal disease Stage: Phase 3.
DEXTENZA: Drug-eluting intracanalicular insert for ocular inflammation and pain Stage: FDA approved.
Ocular Therapeutix, Inc. reported a net loss of $265.9 million for the fiscal year ended Dec 31, 2025, and used $204.9 million of cash in operations, per its annual report to the SEC.
$197.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio